Who are BL-7040's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Group S+T, fingolimob (FTY), FTY720, JYB1904, Standard of Care IST, zilucoplan (RA101495).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bl-7040.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

BL-7040 — Competitive Intelligence Brief

BL-7040 (BL-7040) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: S1P1 receptor modulator. Area: Autoimmune diseases.

phase 2 S1P1 receptor modulator S1P1 Autoimmune diseases Small molecule Live · refreshed every 30 min

Target snapshot

BL-7040 (BL-7040) — BioLineRx, Ltd.. BL-7040 is a small molecule that acts as a sphingosine-1-phosphate receptor 1 (S1P1) modulator.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BL-7040 TARGET	BL-7040	BioLineRx, Ltd.	phase 2	S1P1 receptor modulator	S1P1
Group S+T	Group S+T	Huazhong University of Science and Technology	marketed	S1P receptor modulator	S1P1
fingolimob (FTY)	fingolimob (FTY)	University Hospital, Clermont-Ferrand	marketed	Sphingosine-1-phosphate receptor modulator	S1P1 receptor (sphingosine-1-phosphate receptor 1)
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
JYB1904	JYB1904	Jemincare	phase 3	S1P1 receptor antagonist	S1P1
Standard of Care IST	Standard of Care IST	Biogen	phase 3	S1P receptor modulator	S1P1, S1P3, S1P4, S1P5, S1P6
zilucoplan (RA101495)	zilucoplan (RA101495)	UCB Biopharma SRL	phase 3	S1P receptor modulator	S1P1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (S1P1 receptor modulator class)

AbbVie · 1 drug in this class
Archigen Biotech Limited · 1 drug in this class
AstraZeneca · 1 drug in this class
BioLineRx, Ltd. · 1 drug in this class
Bright Minds Biosciences Pty Ltd · 1 drug in this class
Celtic Pharma Development Services · 1 drug in this class
Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
Eric Stephen Winer, MD · 1 drug in this class
Ferrer Internacional S.A. · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BL-7040 — Competitive Intelligence Brief. https://druglandscape.com/ci/bl-7040. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab